Switching transplant drugs may slash skin cancer risk
NCT ID NCT00133887
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study looked at kidney transplant recipients who already had one skin cancer. It compared two groups: one switched to rapamycin, the other stayed on standard drugs (calcineurin inhibitors). The goal was to see if rapamycin could lower the chance of getting new skin cancers over two years. All participants had to have stable kidney function and no other major health issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Edouard Herriot - Service de Dermatologie
Lyon, 69003, France
Conditions
Explore the condition pages connected to this study.